To report the 5-year failure-free survival (FFS) following HIFU.
This observational cohort study used linked national cancer registry data, radiotherapy data, administrative hospital data and mortality records of 1,381 men treated with HIFU for clinically localised prostate cancer in England. The primary outcome, FFS, was defined as freedom from local salvage treatment and cancer-specific mortality. Secondary outcomes were freedom from repeat HIFU, prostate cancer-specific survival (CSS) and overall survival (OS). Cox regression was used to determine whether baseline characteristics, including age, treatment year, T-stage and International Society of Urological Pathology (ISUP) grade group were associated with FFS.
The median follow-up was 37 months (IQR 20-62). The median age was 65 years (IQR 59-70) and 81% had an ISUP grade group of 1-2. FFS was 96.5% (95% CI 95.4-97.4%) at 1 year, 86.0% (95% CI 83.7-87.9%) at 3 years and 77.5% (95% CI 74.4-80.3%) at 5 years. 5-year FFS for ISUP grade groups 1-5 was 82.9%, 76.6%, 72.2%, 52.3% and 30.8%, respectively (P <0.001). Freedom from repeat HIFU was 79.1% (95% CI 75.7-82.1%), CSS was 98.8% (95% CI 97.7-99.4%) and OS was 95.9% (95% CI 94.2-97.1%) at 5 years.
Four in five men were free from local salvage treatment at 5 years but treatment failure varied significantly according to ISUP grade group. Patients should be appropriately informed with respect to salvage radical treatment following HIFU.
BJU international. 2023 Jul 08 [Epub ahead of print]
Matthew G Parry, Arunan Sujenthiran, Julie Nossiter, Melanie Morris, Brendan Berry, Arjun Nathan, Ajay Aggarwal, Heather Payne, Jan van der Meulen, Noel W Clarke
Department of Health Services Research and Policy, LSHTM., The National Prostate Cancer Audit, Clinical Effectiveness Unit, Royal College of Surgeons of, England., Department of Oncology, University College London Hospitals, London., Departments of Urology, The Christie and Salford Royal Hospitals, Manchester.